Please assess the completion status of the following clinical trial:

Trial Title: S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer meeting 1 of the following criteria:~  * Metastatic disease (M1)~ * Multiple sites of new disease that is clinically obvious metastatic disease (e.g., multiple sites of new osseous disease)~* Measurable or nonmeasurable disease~* No known brain or CNS metastases~* Hormone receptor status:~  * Estrogen-receptor positive\* AND/OR~ * Progesterone-receptor positive\* NOTE: \*Positivity defined as estrogen binding of \> 10 fmol/mg cytosol protein by ligand binding assay or positive by immunohistochemistry~PATIENT CHARACTERISTICS:~Age~* Not specified~Sex~* Female~Menopausal status~* Postmenopausal, as defined by 1 of the following:~  * Prior bilateral oophorectomy~ * More than 12 months since last menstrual period with no prior hysterectomy~ * At least 55 years of age with prior hysterectomy~ * Under 55 years of age with a prior hysterectomy without oophorectomy and with estradiol and follicle-stimulating hormone levels consistent with menopause~Performance status~* Zubrod 0-2~Life expectancy~* Not specified~Hematopoietic~* No bleeding diathesis (e.g., disseminated intravascular coagulation or clotting factor deficiency)~Hepatic~* INR ≤ 1.6~Renal~* Not specified~Other~* HIV negative~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior immunotherapy for recurrent or metastatic disease~Chemotherapy~* No prior chemotherapy for recurrent or metastatic disease~* More than 12 months since prior adjuvant or neoadjuvant chemotherapy~* No concurrent chemotherapy for malignancy~Endocrine therapy~* Prior adjuvant hormonal therapy allowed~* At least 12 months since prior adjuvant luteinizing hormone-releasing hormone (LHRH) analogues~  * Menstrual periods must not have resumed since LHRH therapy~* More than 12 months since prior adjuvant or neoadjuvant aromatase inhibitors (e.g., anastrozole, letrozole, or exemestane)~* More than 12 months since prior fulvestrant~* No prior hormonal therapy for recurrent or metastatic disease~* No other concurrent hormonal therapy for malignancy~* No concurrent hormone replacement therapy~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* No long-term anticoagulant therapy (except antiplatelet therapy)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients receive oral anastrozole once daily on days 1-28.
- Arm II (Type: EXPERIMENTAL): Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete